Dr. Fin Balor Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
About Dr. Fin Balor Laboratories
Dr. Fin Balor Laboratories Private Limited (DFBLPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 April 2022 (Two years and nine months 7 days old ). Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Manorama Basedia and Prachi Dwivedi serve as directors at the Company.
Company Details
-
Location
Bhopal, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MP2022PTC060643
-
Company No.
060643
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Apr 2022
-
Date of AGM
25 Jul 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Dr. Fin Balor Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manorama Basedia
|
Director | 09-May-2024 | Current |
|
Prachi Dwivedi
|
Director | 27-Apr-2022 | Current |
Financial Performance of Dr. Fin Balor Laboratories.
Dr. Fin Balor Laboratories Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. Fin Balor Laboratories?
Unlock access to Dr. Fin Balor Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jan 2024 | Indian Overseas Bank | ₹1.00 M | Open |
How Many Employees Work at Dr. Fin Balor Laboratories?
Dr. Fin Balor Laboratories has a workforce of 0 employees as of Mar 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Fin Balor Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Fin Balor Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
